62 -12 (86) 2025 - Temirova D.V. - ANALYSIS OF SCREENING RESULTS AND TREATMENT METHODS IN ELDERLY WOMEN WITH BREAST CANCER

ANALYSIS OF SCREENING RESULTS AND TREATMENT METHODS IN ELDERLY WOMEN WITH BREAST CANCER

Temirova D.V. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Breast cancer is the most common malignant tumor among women. It is not evenly distributed around the world: the highest incidence rates are observed in England, Denmark, and the United States (30–40%), while the lowest rates are found in Japan, Mexico, and Central Asia (2–10%). Age is one of the main risk factors for breast cancer. The average age at diagnosis is approximately 60 years. More than 40% of all breast cancer cases occur in women aged 60 and older. The likelihood of developing the disease increases with age. According to the World Health Organization, in 2022 there were approximately 2.3 million new cases of breast cancer among women worldwide. In the same year, about 670,000 deaths were recorded due to this disease. The incidence of breast cancer continues to increase year by year in all economically developed countries. In Uzbekistan, the number of breast cancer cases has gradually increased in recent years, and it has become the most common malignant tumor among women.

Keywords: breast cancer, old age, adjuvant treatment, chemotherapy, radiation therapy.

First page

345

Last page

353

For citation:Temirova D.V. - ANALYSIS OF SCREENING RESULTS AND TREATMENT METHODS IN ELDERLY WOMEN WITH BREAST CANCER//New Day in Medicine 12(86)2025 345-353 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

  1. AbeO, AbeR, EnomotoK, etal. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687–717
  2. Albain K, Anderson S, Arriagada R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 2012;379(9814):432–44
  3. Alberini J.L., Meunier В., Denzler B. et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography // Breast Cancer Res. Treat 2000;61:21-32.
  4. Allen В., Campbell 1., Desai S et al Pilot study companng the accuracy of lymphoscintigraphy sentinel lymph node localisation with axillary node dissection in women with operable breast cancer // N. Z. Med. J 2001;114:233-236
  5. Anderson BO et al. (2008) Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer, 202008;113:2221–43.
  6. Anderson W.F., Pfeiffer R.M., Dores G.M.,Sherman M.E. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15(10): 1899−905
  7. Anderson W.F., Pfeiffer R.M., Dores G.M.,Sherman M.E. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15(10): 1899−905
  8. Antoniou A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies // Am. J. Hum. Genet. 2003;72:1117-1130
  9. Arriagada R., Le M. G., Guinebretiere J. M. et al. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients // Ann. Oncol 2003;11:1617-1622
  10. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28(23):3784–96

    file

    download